Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
CLDX's Cash to Debt is ranked higher than
94% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.74 vs. CLDX: No Debt )
CLDX' s 10-Year Cash to Debt Range
Min: 2.73   Max: No Debt
Current: No Debt

Equity to Asset 0.89
CLDX's Equity to Asset is ranked higher than
93% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. CLDX: 0.89 )
CLDX' s 10-Year Equity to Asset Range
Min: -0.51   Max: 0.94
Current: 0.89

-0.51
0.94
F-Score: 4
Z-Score: 24.85
M-Score: 137.33
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1981.08
CLDX's Operating margin (%) is ranked lower than
54% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.30 vs. CLDX: -1981.08 )
CLDX' s 10-Year Operating margin (%) Range
Min: -2023.72   Max: -13.79
Current: -1981.08

-2023.72
-13.79
Net-margin (%) -1983.70
CLDX's Net-margin (%) is ranked lower than
54% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.29 vs. CLDX: -1983.70 )
CLDX' s 10-Year Net-margin (%) Range
Min: -2880.08   Max: -5.41
Current: -1983.7

-2880.08
-5.41
ROE (%) -25.50
CLDX's ROE (%) is ranked higher than
57% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.27 vs. CLDX: -25.50 )
CLDX' s 10-Year ROE (%) Range
Min: -942.8   Max: -3.37
Current: -25.5

-942.8
-3.37
ROA (%) -23.50
CLDX's ROA (%) is ranked higher than
56% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.69 vs. CLDX: -23.50 )
CLDX' s 10-Year ROA (%) Range
Min: -228.19   Max: -2.3
Current: -23.5

-228.19
-2.3
ROC (Joel Greenblatt) (%) -816.62
CLDX's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.14 vs. CLDX: -816.62 )
CLDX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2485.93   Max: -59.59
Current: -816.62

-2485.93
-59.59
Revenue Growth (%) -67.60
CLDX's Revenue Growth (%) is ranked higher than
51% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. CLDX: -67.60 )
CLDX' s 10-Year Revenue Growth (%) Range
Min: -67.6   Max: 73.6
Current: -67.6

-67.6
73.6
EPS Growth (%) 133.60
CLDX's EPS Growth (%) is ranked higher than
98% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. CLDX: 133.60 )
CLDX' s 10-Year EPS Growth (%) Range
Min: -64.6   Max: 133.6
Current: 133.6

-64.6
133.6
» CLDX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

CLDX Guru Trades in Q3 2013

Andreas Halvorsen 672,513 sh (New)
Murray Stahl 26,335 sh (+0.16%)
Jean-Marie Eveillard 550,000 sh (-17.36%)
Chuck Royce 273,000 sh (-31.75%)
Steven Cohen 1,489,700 sh (-62.76%)
» More
Q4 2013

CLDX Guru Trades in Q4 2013

Columbia Wanger 1,671,000 sh (New)
Steven Cohen 3,506,488 sh (+135.38%)
Murray Stahl 26,335 sh (unchged)
Chuck Royce Sold Out
Andreas Halvorsen Sold Out
Jean-Marie Eveillard 135,000 sh (-75.45%)
» More
Q1 2014

CLDX Guru Trades in Q1 2014

Columbia Wanger 2,672,000 sh (+59.9%)
Murray Stahl 26,335 sh (unchged)
Jean-Marie Eveillard Sold Out
Steven Cohen 1,818,631 sh (-48.14%)
» More
Q2 2014

CLDX Guru Trades in Q2 2014

Columbia Wanger 3,583,600 sh (+34.12%)
Murray Stahl 26,335 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with CLDX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2014-03-31 Sold Out 0.01%$16.95 - $31.59 $ 15.91-38%0
Jean-Marie Eveillard 2013-12-31 Reduce -75.45%0.04%$21.51 - $36.71 $ 15.91-38%135000
Jean-Marie Eveillard 2013-06-30 Reduce -45.89%0.02%$11.01 - $16.09 $ 15.9121%665560
George Soros 2012-06-30 Sold Out 0.06%$3.9 - $5.26 $ 15.91262%0
Jean-Marie Eveillard 2012-06-30 Add 260.87%0.02%$3.9 - $5.26 $ 15.91262%1660000
George Soros 2012-03-31 New Buy0.06%$2.77 - $5.46 $ 15.91298%803200
Jean-Marie Eveillard 2012-03-31 Add 360%0.01%$2.77 - $5.46 $ 15.91298%460000
Jean-Marie Eveillard 2011-12-31 Reduce -71.43%$2.11 - $3.21 $ 15.91489%100000
Jean-Marie Eveillard 2011-06-30 New Buy0.01%$3.03 - $4.46 $ 15.91324%350000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.36
CLDX's P/B is ranked higher than
50% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.46 vs. CLDX: 5.36 )
CLDX' s 10-Year P/B Range
Min: 1.25   Max: 50.74
Current: 5.36

1.25
50.74
P/S 530.33
CLDX's P/S is ranked lower than
69% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.40 vs. CLDX: 530.33 )
CLDX' s 10-Year P/S Range
Min: 1.68   Max: 631.2
Current: 530.33

1.68
631.2
EV-to-EBIT -10.88
CLDX's EV-to-EBIT is ranked higher than
50% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 168.09 vs. CLDX: -10.88 )
CLDX' s 10-Year EV-to-EBIT Range
Min: 3.5   Max: 4.6
Current: -10.88

3.5
4.6
Current Ratio 12.06
CLDX's Current Ratio is ranked higher than
95% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.89 vs. CLDX: 12.06 )
CLDX' s 10-Year Current Ratio Range
Min: 1.67   Max: 16.03
Current: 12.06

1.67
16.03
Quick Ratio 12.06
CLDX's Quick Ratio is ranked higher than
96% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.47 vs. CLDX: 12.06 )
CLDX' s 10-Year Quick Ratio Range
Min: 1.67   Max: 16.03
Current: 12.06

1.67
16.03

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.46
CLDX's Price/Net Cash is ranked higher than
91% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CLDX: 6.46 )
CLDX' s 10-Year Price/Net Cash Range
Min: 2.75   Max: 47.3
Current: 6.46

2.75
47.3
Price/Net Current Asset Value 6.44
CLDX's Price/Net Current Asset Value is ranked higher than
90% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CLDX: 6.44 )
CLDX' s 10-Year Price/Net Current Asset Value Range
Min: 2.73   Max: 45.93
Current: 6.44

2.73
45.93
Price/Tangible Book 6.07
CLDX's Price/Tangible Book is ranked higher than
71% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.85 vs. CLDX: 6.07 )
CLDX' s 10-Year Price/Tangible Book Range
Min: 2.18   Max: 55.86
Current: 6.07

2.18
55.86
Price/Median PS Value 24.86
CLDX's Price/Median PS Value is ranked higher than
56% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.41 vs. CLDX: 24.86 )
CLDX' s 10-Year Price/Median PS Value Range
Min: 0.08   Max: 55.45
Current: 24.86

0.08
55.45
Forward Rate of Return (Yacktman) -5.66
CLDX's Forward Rate of Return (Yacktman) is ranked higher than
62% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.80 vs. CLDX: -5.66 )
CLDX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -48.4   Max: -46.2
Current: -5.66

-48.4
-46.2

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:TCE1.Germany
Celldex Therapeutics, Inc., is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. Its drug candidate, rindopepimut (CDX-110), is an immunotherapeutic vaccine that targets the tumor-specific molecule, epidermal growth factor receptor variant III (EGFRvIII). EGFRvIII is a mutated form of the epidermal growth factor receptor (EGFR) that is only expressed in cancer cells and not in normal tissue and can directly contribute to cancer cell growth. Its other drug candidates include CDX-011 and CDX-1127. CDX-011 is an antibody-drug conjugate (ADC) that consists of a fully-human monoclonal antibody, CR011, linked to a potent cell-killing drug, monomethyl-auristatin E (MMAE). The CR011 antibody specifically targets glycoprotein NMB (GPNMB) that is expressed in a variety of human cancers including breast cancer. In December 2011, it completed enrollment of EMERGE, a randomized Phase 2b study of CDX-011 in patients with heavily pre-treated, advanced, GPNMB-positive breast cancer. It has additional clinical and preclinical programs, including CDX-1401, an APC Targeting Technology program, CDX-301, an immune cell mobilizing agent and dendritic cell growth factor and CDX-1135, a molecule that inhibits a part of the immune system called the complement system. The Company's products are derived from a broad set of complementary technologies which have the ability to utilize the human immune system and enable the creation of therapeutic agents. It is using these technologies to develop targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that prevent or treat cancer and other diseases that modify undesirable activity by the body's own proteins or cells. A number of its immunotherapeutic and antibody-drug conjugate drug candidates are in various stages of clinical trials. The Company faces competition from pharmaceutical and biotechnology companies both in the United States and abroad. In the United States, vaccines and immunotherapeutics for human use are subject to The Food and Drug Administration (FDA) approval as 'biologics' under the Public Health Service Act and 'drugs' under the Federal Food, Drug and Cosmetic Act.
» More Articles for CLDX

Headlines

Articles On GuruFocus.com
CLDX up 223%, Cohen Gains Big Apr 23 2013 
Steve Cohen Increases Celldex Up 145% Apr 06 2013 
comment on CLDX Mar 06 2013 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
CELLDEX THERAPEUTICS, INC (CLDX) CEO Anthony S Marucci buys 12,000 Shares Sep 13 2010 
Weekly CFO Buys Highlight: GNMK, RTIX, BKOR, PTEK, CLDX Sep 12 2010 
CELLDEX THERAPEUTICS, INC Reports Operating Results (10-Q) Aug 05 2010 
CELLDEX THERAPEUTICS, INC Reports Operating Results (10-Q) May 06 2010 
cooldecency99 note on CLDX May 01 2010 
CELLDEX THERAPEUTICS, INC (CLDX) CFO Avery W Catlin buys 1,000 Shares Dec 01 2009 


More From Other Websites
Celldex Therapeutics (CLDX) Worth Watching: Stock Rises 9.1% Aug 27 2014
Today's Dead Cat Bounce Stock: Celldex Therapeutics (CLDX) Aug 22 2014
5 Companies Developing New Cancer Drugs Aug 19 2014
CELLDEX THERAPEUTICS, INC. Financials Aug 15 2014
CELLDEX THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report Aug 07 2014
CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 06 2014
Celldex Reports Second Quarter 2014 Results Aug 06 2014
Q2 2014 Celldex Therapeutics, Inc. Earnings Release - After Market Close Aug 06 2014
17 stocks traders are shorting ahead of earnings Aug 04 2014
Celldex Therapeutics Announces Senior Leadership Promotions Jul 30 2014
Celldex Therapeutics (CLDX) Is Today's Perilous Reversal Stock Jul 24 2014
Celldex Therapeutics (CLDX) Is Today's Dead Cat Bounce Stock Jul 18 2014
Celldex to Report Second Quarter 2014 Financial Results and Host Corporate 2014 Objectives Update... Jul 18 2014
Why Immunotherapies Have Made DelMar's Lead Drug A Necessity In Brain Cancer Jul 15 2014
5-Star Biotech Stock Watch: Celldex Therapeutics Jun 25 2014
Today's Perilous Reversal Stock: Celldex Therapeutics (CLDX) Jun 06 2014
Celldex Therapeutics (CLDX) Soars: Stock Adds 12.6% in Session Jun 06 2014
Celldex says Varlilumab continues to demonstrate very favorable profile Jun 02 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK